Cancer specific mortality in insulin-treated type 2 diabetes patients

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Ioacara, Sorin ^a   Guja, Cristian ^a,b   Ionescu Tirgoviste, Constantin ^a,b   Fica, Simona ^a   Roden, Michael ^c,d  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b National Institute of Diabetes   (Romania)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SHORT ACTING INSULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; FOLLOW UP; HUMAN; INSULIN TREATMENT; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PROPENSITY SCORE; URBAN POPULATION; URINARY TRACT CANCER;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT;

EID: 84899752662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093132     Document Type: Article

References (22)

1. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755-1765.
2. Hemkens LG, Bender R, Grouven U, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744.
3. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, et al. (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52: 1745-1754.
4. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-85.
5. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328.
6. Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Sabau S, et al. (2011) Improvements in life expectancy in adult type 2 diabetes patients in the last six decades Diab Res Clin Pract 92: 400-4.
7. WHO Collaborating Centre for Drug Statistics Methodology (2012) ATC/DDD Index. Available: www.whocc.no/atc-ddd-index. Accessed 2012 Sept 14.
8. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94: 496-509.
9. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, et al (2012) Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 55: 2929-2937.
10. Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, et al. (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54: 2254-2262.
11. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 55: 51-62.
12. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
13. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52: 2499-2506.
14. Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1971-1973.
15. Mannucci E, Monami M, Balzi D, Cresci B, Pala L (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33: 1997-2003.
16. Morden N, Liu S, Smith J, Mackenzie T, Skinner J, et al. (2011) Further exploration of the relationship between insulin glargine and incident cancer-a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965-1971.
17. Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55: 644-653.
18. Renehan AG (2012) Insulin analogues and cancer risk: the emergence of second-generation studies. Diabetologia 55: 7-9.
19. Stefansdottir G, Zoungas S, Chalmers J, Kengne AP, Knol MJ (2011) Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 54: 1608-1614.
20. van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55: 654-665.
21. Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Timevarying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54: 2263-2271.
22. Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55: 948-958.